Anktiva（前称N-803）

Anktiva is a first-class cytokine interleukin -15 (IL-15) agonist immunotherapy for non-muscular invasive bladder cancer. The combination of this drug and its receptor leads to the proliferation and activation of natural killer cells, CD8+ cells and memory T cells. Previously, the FDA has obtained breakthrough therapy and fast-track designation for treating BCG-unresponsive NMIBC CIS, as well as fast-track designation for BCG-unresponsive NMIBC papillary and BCG-newly treated NMIBC CIS.

Anktiva (formerly known as N-803)_ Hong Kong Jimin Pharmaceutical

[Anktiva indications]

Anktiva is an interleukin -15 (IL-15) receptor agonist, which is suitable for treating adult patients with non-invasive bladder cancer (NMIBC) with or without papillary tumor (CIS) who are unresponsive to BCG.

[Anktiva Dosage and Usage]

For intravesical use only.

Induction therapy: 400mcg of BCG was injected into bladder once a week for 6 weeks. If the complete remission is not achieved in the third month, the second induction treatment can be performed.

Maintenance treatment: In the 4th, 7th, 10th, 13th and 19th months, 400mcg BCG vaccine was injected into the bladder once a week for 3 weeks. For patients who have sustained complete remission after the 25th month, they can be given BCG maintenance drip once a week at the 25th month, 31st month and 37th month for 3 weeks.

Intravesical instillation is only performed after dilution. The total time from vial puncture to bladder instillation should not exceed 2 hours.

For dilution and administration instructions, please refer to the complete prescription information.

[Anktiva dosage form and strength]

400mcg/0.4mL, transparent to microemulsion white, colorless to yellowish solution, packed in a single-dose vial, diluted for intravesical instillation.

[Anktiva contraindication]

None.

[Anktiva Warnings and Precautions]

Delayed cystectomy may lead to the development of metastatic bladder cancer, which may be fatal.

[Anktiva is used in special people]

Pregnancy: May cause harm to the fetus. Inform women of the potential risks of reproductive potential to the fetus and take effective contraceptive measures.

[Anktiva Adverse Reaction]

The most common (≥15%) adverse reactions (including abnormal laboratory tests) include increased creatinine, dysuria, hematuria, frequent urination, urgency, urinary tract infection, elevated blood potassium, musculoskeletal pain, chills and fever.

Note: If there is any new packaging for drugs, the new packaging shall prevail. The above information comes from the Internet or translated by student volunteers in medical colleges and universities (if there are any mistakes or omissions, please help me to correct them). It is for internal discussion of medical staff only, without any basis for medication. Please consult the attending physician for specific medication guidelines.